Format

Send to

Choose Destination
J Neurosci Res. 2009 Feb 15;87(3):599-608. doi: 10.1002/jnr.21890.

Minocycline: a neuroprotective agent for hypoxic-ischemic brain injury in the neonate?

Author information

1
Perinatal Research Centre, University of Queensland Centre for Clinical Research, Herston, Queensland, Australia. k.buller@uq.edu.au

Abstract

Minocycline is a second-generation tetracycline and a potential neuroprotective intervention following brain injury. However, despite the recognized beneficial effects of minocycline in a multitude of adult disease states, the clinical application of minocycline in neonates is contentious. Tetracyclines, as a class, are not usually administered to neonates, but there is compelling evidence that minocycline reduces brain injury after neonatal hypoxic-ischemic brain injury. This Review focuses on the evidence for minocycline use in neonates by considering aspects of pharmacology, drug regimens, functional outcomes, and mechanisms of action.

PMID:
18831005
DOI:
10.1002/jnr.21890
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center